AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00621842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine regular tablet formulation
Description: Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.
Study NCT00621842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine novel formulation
Description: Participants will have the option of trying a novel formulation of lamotrigine tablets instead of the lamotrigine regular formulation tablets. The dosing will remain the same regardless of which type of lamotrigine tablet is used.~Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.
Study NCT03136588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feedback using ICT based monitoring system
Description: In case of a missed immunosuppressant dose, the first violation does not generate a feedback while the second one does within one hour at the break of the ±3 hour range from the fixed dosing time. Up to two additional alarms/texts are sent at an interval of 30 minutes if the dose is still not taken after the feedback. For any discrepancy between the dosage taken and the dosage prescribed, a feedback is sent within 1 hour from the moment of recognition. Again, the first violation goes without response, while any violation after that generates feedbacks. Similarly, if a dose is taken outside of the allowed ±3 hour dosing time range, a feedback is sent within 1 hour of recognition, starting with the second violation.
Study NCT01878539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coagulometer
Study NCT01878539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training programme
Study NCT04356352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: 0.5 mg/kg esmolol to a max of 50mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
Study NCT04356352 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline water administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
Study NCT03478735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Greater Occipital Nerve Block at C2
Description: Ultrasound guided injection
Study NCT03478735 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Landmark-Based Greater Occipital Nerve Block
Description: Traditional landmark-guided technique at the superior nuchal line. This approach relies solely on superficial bone-based anatomic landmarks to infiltrate local anesthetic and corticosteroid around the nerve at the level of the superior nuchal line.
Study NCT02846701 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: duloxetine
Description: The concentration of duloxetine is measured by liquid chromatography coupled to tandem mass spectrometry on blood sample
Study NCT06039618 — intervention group
Intervention type: OTHER
Intervention: Referral to Centre of Higher Organizational Level
Description: Referral to Centre of Higher Organizational Level. This means referral from a primary neonatal care center to a secondary one, or from the secondary to the tertiary center.
Study NCT02610452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clown therapy
Description: The clowns intervene by twos: a game takes place.~1. The game requires the active presence of a number of potential players in the room (patient, family, caregivers) and takes into account body position, emotional state, the general atmosphere.~2. The clowns initiate a game proposal: provisional staging of clown characters based on imagination/improvisation which engages a physicality and a basic emotional state.~3. The original game proposal is adjusted according to mutual empathy with those present.~4. The game is developed on the model of theatrical improvisation: an original creation that has scenic quality comparable to that of a complete representation. Improvisation time varies depending on the condition of the person, his/her desire to participate, choosing the main theme.~5. The final stage of the game is preparing all actors for separation: restitution of roles, revisiting the paths traveled.
Study NCT01371734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release
Description: Subjects randomized to DVS SR treatment arm will receive 25, 35, or 50 mg/day based on subject weight at the Baseline visit.
Study NCT01371734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release
Description: Subjects randomized to DVS SR treatment arm will receive 20, 25, or 35 mg/day based on subject weight at the Baseline visit.
Study NCT01371734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to the Placebo treatment arm will receive placebo tablets
Study NCT02052401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Domiciliary Intervention
Description: Two time domiciliary application of an standardized protocol consisting of: a) evaluation of pharmacological and non pharmacological therapies adherence. b) application of a Checklist of home safety measures. c) development of a patient oriented occupational routine d) education in strategies for elderly global stimulation e) education strategies for identifying red flags and for correct use of health services.
Study NCT03839589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Adapated (MBSR-A)
Description: Mindfulness-based stress reduction (MBSR) is a group-based intervention developed in 1979 by Dr. Jon Kabat-Zinn to provide mindfulness training in order to decrease stress and improve overall well-being. MBSR has been shown to be effective for a series of patient outcomes including depression, anxiety disorders, sleep disorders, and chronic pain management. MBSR is a structured intervention delivered through an 8-week course of up to 30 participants who meet for 2.5 hours per week.
Study NCT03839589 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness Based Stress Reduction Adapated (MBSR-A)
Description: Mindfulness-based stress reduction (MBSR) is a group-based intervention developed in 1979 by Dr. Jon Kabat-Zinn to provide mindfulness training in order to decrease stress and improve overall well-being. MBSR has been shown to be effective for a series of patient outcomes including depression, anxiety disorders, sleep disorders, and chronic pain management. MBSR is a structured intervention delivered through an 8-week course of up to 30 participants who meet for 2.5 hours per week.
Study NCT03595410 — intervention group
Intervention type: OTHER
Intervention: Recurrence laryngeal cancer
Description: Recurrence laryngeal cancer has a wide range of invasion, rapid progression and poor prognosis.
Study NCT01217970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast 20mg
Description: Ibudilast 20mg BID
Study NCT01217970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast 50mg
Description: Ibudilast 50mg BID
Study NCT01217970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Study NCT02312232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa, carbidopa, ODM-104
Study NCT02312232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa, carbidopa, ODM-104
Study NCT01847391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-6615
Description: GS-6615 tablet(s) administered orally once daily
Study NCT01847391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet(s) to match GS-6615 administered orally once daily
Study NCT02617823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral position
Description: patients placed on their left side after epidural catheter insertion
Study NCT01316276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amikacin for inhalation
Description: * Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered in two consecutive extension periods, each consisting of 6 cycles for a total of 12 cycles. Each cycle consists of 28 days on-treatment followed by 28 days off-treatment.
Study NCT04434690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral total knee arthroplasty
Description: Two surgeons bilateral TKA group
Study NCT04434690 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sequenced bilateral TKA
Description: Single surgeon bilateral TKA group
Study NCT04200807 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound Cardiac Output Monitor (USCOM 1A)
Description: doplerometry with USCOM and echocardiograph is made for assessing central blood flow and spectroscopy with NONIN- for the blood flow in individual peripheral organs (brain and kidney)
Study NCT01126996 — intervention group
Intervention type: PROCEDURE
Intervention: Venepuncture
Description: 1. Venepuncture and blood sample collection in 2010 in a sample of children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.~2. A booster dose of a MenC conjugate vaccine (optional).
Study NCT02599181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: propanol-biphenol: Kodan
Description: WITH-group, the skin is disinfected with an aerosolized alcoholic solutionpropanol-biphenol: Kodan, Schülke \& Mayr, Zurich, Switzerland.
Study NCT02795559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose
Description: 75g glucose dissolved in 300ml water
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pegaspargase
Description: Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization
Study NCT03020030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erwinia asparaginase
Description: Only for patients with Pegaspargase allergy or silent inactivation.
Study NCT03536741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Intravenous Anesthetic
Description: General Intravenous Anesthetic
Study NCT02755649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Study NCT02755649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Study NCT02547688 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal High Flow
Study NCT01049178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Silymarin
Description: Dose Level 1: 1 capsules (1 cap at 140mg/cap) given three times per day for a total daily dose of 420 mg 28-days post Dose Level 1 Dose Level 2: 3 capsules (3 caps at 140mg/cap = 420 mg) given three times per day for a total daily dose of 1260 mg Day 56 (28-days post Dose Level 2) Dose Level 3: 5 capsules (5 caps at 140mg/cap = 700 mg) given three times per day for a total daily dose of 2100 mg Day 84 (28-days post Dose Level 3) We will evaluate change from baseline at each dose to determine the minimum effective dose.
Study NCT01049178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Silymarin, maintenance dose
Description: The maintenance Silymarin dose will be selected based on the dose escalation study and will be dosed PO three times daily as recommended. Silymarin will be provided as a capsule S. marianum (70-80% silymarin), along with an identical appearance placebo capsule created by our investigational pharmacyAt each visit a questionnaire regarding daily symptoms and disease control, the asthma control test (ACT) will be completed, eNO measured, urine collected, spirometry (lung function) measured, venipuncture performed for blood collection (20 mL), as well as assessment of acceptability, toxicity, and masking.
Study NCT01049178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01602393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 1x
Description: oral tablet, 1x, once a day in the morning for 48 weeks
Study NCT01602393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 2x
Description: oral tablet, 2x, once a day in the morning for 48 weeks
Study NCT01602393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 3x
Description: oral tablet, 3x, once a day in the morning for 48 weeks
Study NCT01609452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blisibimod
Study NCT01609452 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02873338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dociparstat sodium
Description: Subjects received 4 mg/kg dociparstat intravenous (IV) bolus followed by doses of 0.125 or 0.25 mg/kg/hr dociparstat given on Days 1 through 7 with standard induction therapy, on Days 1 through 5 or 7 with standard re-induction therapy, and on Days 1, 3, and 5 with standard consolidation therapy.
Study NCT02873338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Description: Subjects received 12 mg/m2/day idarubicin by slow (10 to 15 minutes) intravenous (IV) injection daily on Days 1, 2 and 3 of induction therapy, and on Days 1 and 2 of re-induction therapy.
Study NCT02873338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Subjects received 12 mg/m2/day idarubicin by slow (10 to 15 minutes) intravenous (IV) injection daily on Days 1, 2 and 3 of induction therapy, and on Days 1 and 2 of re-induction therapy.
Study NCT02873338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Subjects received 100 mg/m2/day cytarabine by continuous intravenous (IV) infusion on Days 1 through 7 of induction therapy and on Days 1 through 5 of re-induction therapy. During consolidation therapy, subjected received 1.0 g/m2 cytarabine IV infusion given over 3 hours every 12 hours on Days 1, 3, and 5.
Study NCT02873338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Subjects received 100 mg/m2/day cytarabine by continuous intravenous (IV) infusion on Days 1 through 7 of induction therapy and on Days 1 through 5 of re-induction therapy. During consolidation therapy, subjected received 1.0 g/m2 cytarabine IV infusion given over 3 hours every 12 hours on Days 1, 3, and 5.
Study NCT04292314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months
Study NCT04292314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella Sativa Oil
Description: Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months
Study NCT04292314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.
Study NCT04292314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Honey
Description: Natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.
Study NCT04292314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.
Study NCT04292314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Description: deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.
Study NCT04292314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood transfusion session
Description: Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
Study NCT04292314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood transfusion session
Description: Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
Study NCT02386826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: Dose Escalation: INC280 by mouth (PO) twice daily for 28 days according to the following schedule until the maximum tolerated dose (MTD) is determined:~Dose Level 1 (starting dose): 200 mg (divided dose of 100 mg twice per day) Dose Level 2: 400 mg (divided dose of 200 mg twice per day) Dose Level 3: 800 mg (divided dose of 400 mg twice per day)~Dose Expansion: INC280 PO twice daily at the MTD determined in the dose escalation phase
Study NCT02386826 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab: 10 mg/kg IV every 2 weeks. Patients with unresectable GBM will be given 15 mg/kg IV every 4 weeks.
Study NCT02508909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Videoscopic ilioinguinal dissection
Description: Inguinal dissection is performed after subcutaneous inflation via three ports. Iliac dissection is obtained through a pro-peritoneal access.
Study NCT04499287 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 15-minute walk at preferred walking speed.
Study NCT04499287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 15-minute walk at preferred walking speed.
Study NCT04499287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15-minute walk at preferred walking speed.
Study NCT04499287 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fiber
Description: 9 grams soluble fiber
Study NCT04499287 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fiber
Description: 9 grams soluble fiber
Study NCT04499287 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber
Description: 9 grams soluble fiber
Study NCT04499287 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: control
Study NCT04499287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: control
Study NCT04499287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: control
Study NCT03534375 — intervention group
Intervention type: OTHER
Intervention: The study is an observational cross sectional study
Description: An intervention will not be performed
Study NCT03705429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TC-H x Paclitaxel (P) + Trastuzumab(T)
Description: chemotherapy
Study NCT03705429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TC-H x Paclitaxel (P) + Trastuzumab(T)
Description: chemotherapy
Study NCT04592146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frailty multicomponent intervention supported by POSITIVE
Description: This technology mainly consists in a home monitoring kit periodically measuring gait speed, involuntary weight loss and power in the lower limb. Furthermore, through a tablet device, other relevant information (e.g. state of mind, activities of daily living-ADLs, etc.) is collected. The same device is used to enhance communication with the clinical team and follow the tailored intervention
Study NCT04592146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frailty multicomponent intervention
Description: This intervention is based on 3 main pillars: medication review (to avoid polypharmacy), tailored nutritional recommendations and a tailored physical activity plan based on the VIVIFRAIL program.
Study NCT04592146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frailty multicomponent intervention
Description: This intervention is based on 3 main pillars: medication review (to avoid polypharmacy), tailored nutritional recommendations and a tailored physical activity plan based on the VIVIFRAIL program.
Study NCT01551030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Buparlisib will be administered at a dose of 100 mg orally once daily (two 50 mg capsules) continuously. Intra-patient dose reduction may be required depending on the type and severity of the individual toxicity encountered. Re-staging imaging studies will be performed after every two cycles of treatment (one cycle = 4 weeks). Patients may continue on study as long as they are tolerating therapy and are free of disease progression.